DBS System attracts Swiss pension fund as an investor

Please login or
register

Stefan Kyora

04.05.2017
DBS System Hemaxis

Medtech startup DBS System has closed a CHF2.5million Series A financing round. The investment of the new shareholder was led by investiere with CHF700k coming from the Swiss pension fund Nest. With this investment, DBS System will industrialize its second generation HemaXis blood collection device.

DBS System focusses on devices to collect and prepare blood samples in a less invasive, easier, cheaper, safer manner with precision and industry standard processes. The company has just closed its Series A financing round. The CHF 2.5M investment round was completed with CHF 1.0M coming from DBS System’s existing shareholders and private business angels and the additional CHF 1.5M was led by investiere.ch with CHF 0.8M coming from investiere.ch’s business angels and CHF 0.7M from the Swiss pension fund Nest. Nest is building a Swiss venture portfolio in partnership with investiere.ch and is systematically co-investing alongside investiere.ch’s business angels. Nest’s investment in DBS System is the first example of this partnership. “Nest makes their investment decision based on the due diligence of investiere's investment managers and their private investor community, matching the private investments”, explained Eric Ödman, co-founder and CEO of DBS System to startupticker.

First product already on the market
DBS System launched its first product HemaXis DB for whole blood collection at the end of 2015 with sales to pharmaceutical companies and research hospital labs who tested and developed protocols for the analysis that would be run on the blood samples collected by the device.

Leveraging the power of the customers
The collaboration with customers is an important success factor for DBS. “Our strong B2B partnership model with large commercial labs that enables us to fully utilize our IP in a commercially viable manner while leveraging their power to build awareness of our technology and have our devices prescribed though their distribution networks is our most important success factor”, says Eric Ödman.

Typical customers are established private labs that run blood tests for various institutions. “They are interested in our device because it is more convenient for the patient, it’s easy to transport without the need for cold storage, and it already fits within their workflow because the blood samples are stored on an industry standard blood collection card”, comments Eric Ödman. Depending on the lab, the blood samples collected with the DBS device can be used for a wide range of tests especially for clinical chemistry, drug screening, biomarker detection, and genetic testing.

The new funds will be used to enable the acquisition of new customers especially in the US, marketing initiatives, and the industrialization of the second generation device, HemaXis DP, for plasma and serum generation.

About Hemaxis
DBS System produces blood collection devices that leverage advanced microfluidic technology, greatly simplifying and reducing the cost of blood sampling without modifying existing lab analysis workflows. DBS System aims to establish itself as the leading manufacturer of medical devices for collecting and preparing micro samples of whole blood, plasma and serum with its patented HemaXis platform of microfluidic devices.

0Comments

More news about

DBS System SA

Company profiles on startup.ch

DBS System SA

rss